Post-earnings recap
Reported
Thu, Oct 25, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite beating EPS expectations, ResMed's stock fell by 1.31% following the earnings report. The lack of revenue data and guidance may have contributed to investor uncertainty. Management's cautious tone regarding market challenges could also be influencing the stock's performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.49 | N/A | +6.99% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the current market conditions while remaining hopeful about future innovations. They did not provide any forward guidance, leaving investors without clear expectations.
Management highlighted ongoing challenges in the market.
They expressed optimism about future product developments.
No specific guidance was provided for upcoming quarters.